Viracta Therapeutics Inc (VIRX) News

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Viracta Therapeutics Announces New Employment Inducement Grants

SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with...

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically...

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]